Free Antiretrovirals Must Not Be Restricted Only to Treatment-Naive Patients
نویسندگان
چکیده
D espite the " 3 by 5 " initiative [1], which aims to treat 3 million people with antiretrovirals (ARVs) by the end of 2005, access to ARVs in resource-poor settings remains limited. Moreover, in some ARV-access programmes, free ARVs are provided only, or preferentially, to patients who are ARV naive. Treatment restricted to patients who are ARV naive was initially the case in Uganda, with the free ARVs provided by the Multi-Country AIDS Programme and the Presidential Emergency Plan for AIDS Relief. While in the policy documents of both projects it was not stated that free ARVs should be given preferentially to ARV-naive patients, many physicians involved in the roll-out of ARVs in Uganda felt that this was what these projects were recommending. Indeed, the Ministry of Health's " Antiretroviral Treatment Policy for Uganda " stated that " those who are clinically eligible and can afford to pay for ART will be encouraged to do so. Those already in privately provided and privately paid ART should be encouraged to remain in this situation. Others who become clinically eligible over time and have the ability to pay or have a third party able to pay in their place or cost share with them, should pay full cost for ART, whether they avail themselves of treatment provided in the public or private sector " [2]. These policy statements were interpreted by many clinicians to mean that patients who are already paying for their drugs can afford to do so and are not a priority for free drugs. In this essay, we explain the rationale for restricting free access to treatment-naive patients, and then we outline the reasons why such restriction is highly problematic. There are four principal reasons why free ARVs are being restricted to treatment-naive patients. Firstly, ARV treatment regimens are more predictable in ARV-naive patients [3]. Programmes limited to this population will provide what donors most desire: good outcomes. Secondly, ARV-naive patients will usually respond readily to less expensive fi rst-line ARV regimens, and only a few will require more complex and costly second-line ARVs. Thirdly, results of programmes are easier to compare, because similar ARV regimens are started in more homogeneous, comparable populations. And fi nally, it is often believed that patients who in the past have been able to buy ARVs should continue to do so. There are, however, serious problems with this strategy of restricted access. …
منابع مشابه
Treatment of Chronic Hepatitis B with Tenofovir
Background:Tenofovir is among the first-line treatments for chronic hepatitis B (CHB) virus infection. We evaluated the efficacy of Tenofovir in the treatment of Iranian adult patients with CHB. Methods: In a retrospective study, we evaluated 154 HBsAg positive patients referred to Sadoughi hospital in Yazd-Iran for treatment ...
متن کاملDeferasirox in Chelation Naive Children with Transfusional Iron Overload in Basra, Iraq: A Two-Year Single Center Study
Background: Effective management of iron overload in patients receiving long-term blood transfusion requires assessment and monitoring of both severity of iron overload and excessive iron chelation. We aimed to evaluate the efficacy and safety of Deferasirox (DFX) in chelation naive patients with transfusion dependent thalassemia and sickle cell disease. Methods: Chelation naive patients with ...
متن کاملDeterminants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
BACKGROUND Identification of the determinants of access to investigational drugs is important to promote equity and scientific validity in clinical research. We aimed to analyze factors associated with the use of experimental antiretrovirals in Italy. METHODS We studied participants in the Italian Cohort of Antiretroviral-Naive Patients (ICoNA). All patients 18 years or older who had started ...
متن کاملA Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study
This study was designed to examine the antidepressant effect of celecoxib (200 mg/day) augmentation of sertraline in the treatment of female patients with first episode of major depression over 8 weeks of therapy.Thirty female outpatients diagnosed with first episode of major depression, were recruited for this study. Participants were randomly assigned into two equal groups receiving either se...
متن کاملA Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study
This study was designed to examine the antidepressant effect of celecoxib (200 mg/day) augmentation of sertraline in the treatment of female patients with first episode of major depression over 8 weeks of therapy.Thirty female outpatients diagnosed with first episode of major depression, were recruited for this study. Participants were randomly assigned into two equal groups receiving either se...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- PLoS Medicine
دوره 2 شماره
صفحات -
تاریخ انتشار 2005